Search Results for 'biosimilars patient'

biosimilars patient published presentations and documents on DocSlides.

ASBM Biosimilars US Prescribers and Biosimilars Naming
ASBM Biosimilars US Prescribers and Biosimilars Naming
by min-jolicoeur
Kevin Olson, CEO. Industry Standard Research. Kev...
Biosimilars in RA:  A Blessing or a Curse?
Biosimilars in RA: A Blessing or a Curse?
by conchita-marotz
Introduction/Overview . What Is a Biosimilar?. Di...
Application of Biosimilars in RA IN Clinical Practice:
Application of Biosimilars in RA IN Clinical Practice:
by conchita-marotz
Key Issues and Challenges.  . Introduction. Diff...
Building a  Biosimilars  Pathway in the U.S.
Building a Biosimilars Pathway in the U.S.
by attentionallianz
Richard . Dolinar. , MD. Endocrinologist, Chairman...
  What is the value of Real-World Evidence for Biosimilars?
  What is the value of Real-World Evidence for Biosimilars?
by bitsy
Disclaimer. This panel is moderated by Dr. Delphin...
Latin American Biologics/Biosimilars Conference
Latin American Biologics/Biosimilars Conference
by giovanna-bartolotta
Presented by . the Alliance for Safe Bioloigic . ...
ASBM Biosimilars
ASBM Biosimilars
by phoebe-click
US Prescribers and Biosimilars Naming. Kevin Olso...
Synergy Satellite Event - Biosimilars in colorectal cancer
Synergy Satellite Event - Biosimilars in colorectal cancer
by mia
– what's your gut feeling?. 25th Anniversary EAH...
Acceptable changes in quality attributes of glycosylated bi
Acceptable changes in quality attributes of glycosylated bi
by debby-jeon
Schiestl M, Stangler T, Torella C, et al. . Nat B...
United Spinal Association
United Spinal Association
by alida-meadow
August, 2014. Biologics & Biosimilars: . An O...
Distinguishable INNs: A Global Solution
Distinguishable INNs: A Global Solution
by trish-goza
Richard . Dolinar. , MD. Chairman, Alliance for S...
PhAMA Position on Biosimilar Medicines
PhAMA Position on Biosimilar Medicines
by celsa-spraggs
Ms. Leah Goodman. Contents. Key Messages. An Over...
Latin American Physician Perspectives on Biosimilars
Latin American Physician Perspectives on Biosimilars
by celsa-spraggs
Presented at the . Latin American Biologics/Biosi...
Budget impact and cost-effectiveness of oncology
Budget impact and cost-effectiveness of oncology
by roxanne
biosimilars. Prof. dr. Steven Simoens. Health econ...
1 Immunogenicity   The key safety issue for biosimilars
1 Immunogenicity The key safety issue for biosimilars
by gelbero
Prof. Ibrahim A. . Alsarra. Professor . of . Phar...
Biosimilars  and biologics –
Biosimilars and biologics –
by gelbero
What does personalisation . mean . for you?. Ian N...